NCT00800787View on ClinicalTrials.gov

Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

April 30, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

September 30, 2010

Conditions

Hepatitis B, Chronic

Interventions

BIOLOGICAL

Nabi-HB

"Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.~Dosage will be according to each patients body weight, as follow:~\< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are \<150 IU/ML \> 75 Kg: 1,000 IU weekly"